![[Webinar] Understanding Gene Therapy, Part 3 - Galgt2 and Dup2 - December 2017 muscular bridge tedavisi](https://i.ytimg.com/vi/ddVym0LXLC8/maxresdefault.jpg)
As part of our ongoing series on Understanding Gene Therapy, PPMD hosted a webinar with Dr. Kevin Flanigan, Director of the Center for Gene Therapy at Nationwide Children’s Hospital. Dr. Flanigan helped explain two gene therapy technologies that he and his team at Nationwide are exploring: GALGT2 and Dup2. This webinar is the third in our series on Gene Therapy where we are bring leaders in gene therapy technology to you to discuss their latest projects and provide an update on this incredibly exciting and expanding field.
As you are aware, PPMD is expanding our Gene Therapy Initiative so that we can continue to provide funding to some of this new gene therapy technology, at critical times in their development process. This bridge funding, such as the $2.2 million grant we gave to Nationwide earlier this year for microdystrophin and the $250,000 we gave to Eric Olson for his work with CRISPR, help us, as a community, ensure that these therapies are safe and effective and have the funding they need to continue to move forward.
There is so much promise in gene therapy and with your commitment to PPMD, we believe we can continue the incredible momentum we are seeing in this field. If you haven’t given to PPMD’s Gene Therapy Initiative, please consider making a donation today. Thanks to the Rice Family, all donations made toward our ambitious goal of $400,000 will be matched dollar for dollar!
DONATE TODAY: www.EndDuchenne.org/Match
[Webinar] Understanding Gene Therapy, Part 3 - Galgt2 and Dup2 - December 2017 muscular bridge tedavisi | |
| 9 Likes | 9 Dislikes |
| 1,272 views views | 3.09K followers |
| Non-profits & Activism | Upload TimePublished on 15 Dec 2017 |
Không có nhận xét nào:
Đăng nhận xét